News NICE backs Alimera’s three-year uveitis implant An implant developed by Alimera Sciences has been recommended by NICE to treat an inflammatory eye disease that can cau
Partner Content Partner Content Your Latest Ophthalmology News for SMi’s Ophthalmic Drugs 20... Ophthalmic Drugs Conference London
R&D On genomics, NGS, and doing much more good than bad, with Ma... Markus Vossman, Germany general manager at Illumina, discusses innovative genomic applications and projects in the region.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
